The present invention relates, in part, to chimeric proteins comprising at least one targeting moiety that recognizes and binds SIRP1α and their use as diagnostic and therapeutic agents. The present invention further relates to pharmaceutical compositions comprising the chimeric proteins and their use in the treatment of various diseases.